Patents by Inventor Claus Fittschen

Claus Fittschen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Hydroxyquinoline derivatives
    Patent number: 8158799
    Abstract: Compounds of the formula I in which X, Y, R1, R1?, R2, R3 have the meanings indicated in Claim 1, are inhibitors of cell proliferation and can be employed for the treatment of tumors.
    Type: Grant
    Filed: November 14, 2006
    Date of Patent: April 17, 2012
    Assignee: Merck Patent Gesellschaft MIT Meschraenkter Haftung
    Inventors: Oliver Schadt, Dieter Dorsch, Claus Fittschen, Matthias Grell
  • Hydroxyquinoline Derivatives
    Publication number: 20080312278
    Abstract: Compounds of the formula I in which X, Y, R1, R1?, R2, R3 have the meanings indicated in claim 1, are inhibitors of cell proliferation and can be employed for the treatment of tumours.
    Type: Application
    Filed: November 14, 2006
    Publication date: December 18, 2008
    Inventors: Oliver Schadt, Dieter Dorsch, Claus Fittschen, Matthias Grell
  • Chromenone and chromanone derivatives as integrin inhibitors
    Patent number: 6849646
    Abstract: The invention relates to compounds having formula (I), wherein R1, R2, R3, R4, R5, R7, R8, R11, Z, m and n have the meaning cited in claim 1, and to the physiologically acceptable salts and solvates which can be used as integrin inhibitors, especially in the prophylaxis and treatment of circulatory diseases, in case of thrombosis, myocardial infarction, coronary heart diseases, arteriosclerosis, osteoporosis, pathologic processes caused or propagated by angiogenesis and in tumor therapy.
    Type: Grant
    Filed: October 14, 1999
    Date of Patent: February 1, 2005
    Assignee: Merck Patent GmbH
    Inventors: Claus Fittschen, Simon Goodman, Joachim März, Peter Raddatz, Matthias Wiesner
  • Adhesion receptor antagonists
    Patent number: 6602876
    Abstract: Compounds of the formula I wherein R1, R2 and R3 have the meanings defined herein, and also their physiologically acceptable salts, inhibit the binding of fibrinogen to the corresponding receptor and can be employed for the treatment of thromboses, osteoporoses, oncoses, apoplexy, cardiac infarct, ischaemias, inflammations, arteriosclerosis and osteolytic disorders.
    Type: Grant
    Filed: November 2, 1995
    Date of Patent: August 5, 2003
    Assignee: Merck Patent GmbH
    Inventors: Joachim Gante, Horst Juraszyk, Peter Raddatz, Hanns Wurziger, Sabine Bernotat-Danielowski, Guido Melzer, Matthias Wiesner, Claus Fittschen
  • Cyclic peptide derivatives
    Patent number: 6333308
    Abstract: Compounds of the formula I cyclo-(Arg-X-Asp-R1)  I in which X is Gly, Ala or NH—NH—CO, R1 is a radical of the formula II  and R2,R3 and R4 have the meanings indicated in claim 1, and their salts, can be used as integrin inhibitors, in particular for the prophylaxis and treatment of disorders of the circulation, in thrombosis, cardiac infarct, coronary heart disorders, arteriosclerosis, in pathological processes which are supported or propagated by angiogenesis and in tumour therapy.
    Type: Grant
    Filed: October 7, 1999
    Date of Patent: December 25, 2001
    Assignee: Merck KGaA
    Inventors: Gunter Holzemann, Claus Fittschen, Simon Goodman
  • Adhesion receptor antagonists
    Patent number: 6204280
    Abstract: Compounds of the formula I wherein R1, R2 and R3 have the meanings defined herein, and also their physiologically acceptable salts, inhibit the binding of fibrinogen to the corresponding receptor and can be employed for the treatment of thromboses, osteoporoses, oncoses, apoplexy, cardiac infarct, ischaemias, inflammations, arteriosclerosis and osteolytic disorders.
    Type: Grant
    Filed: September 30, 1998
    Date of Patent: March 20, 2001
    Assignee: Merck Patent Gesellschaft mit berschrankter Haftung
    Inventors: Joachim Gante, Horst Juraszyk, Peter Raddatz, Hanns Wurziger, Sabine Bernotat-Danielowski, Guido Melzer, Matthias Wiesner, Claus Fittschen